When was ehlers danlos discovered

Content on WhatAnswers is provided "as is" for informational purposes. While we strive for accuracy, we make no guarantees. Content is AI-assisted and should not be used as professional advice.

Last updated: April 17, 2026

Quick Answer: Ehlers-Danlos syndrome was first formally described in 1901 by Danish physician Edvard Lauritz Ehlers and later named in 1908 by French physician Henri-Alexandre Danlos, marking the official discovery of the condition.

Key Facts

Ehlers-Danlos syndrome was first identified in 1901 by Danish physician Edvard Lauritz Ehlers
French physician Henri-Alexandre Danlos contributed key research in 1908, leading to the syndrome's name
The condition affects approximately 1 in 5,000 people worldwide
There are 13 recognized subtypes of Ehlers-Danlos, with hypermobile type being the most common
In 2017, the International Consortium on Ehlers-Danlos Syndromes updated diagnostic criteria

Overview

Ehlers-Danlos syndrome (EDS) is a group of inherited connective tissue disorders characterized by joint hypermobility, skin hyperextensibility, and tissue fragility. Though symptoms were observed centuries earlier, the condition was first formally documented in the early 20th century.

The medical community credits Danish dermatologist Edvard Lauritz Ehlers with the first clinical description in 1901, followed by French physician Henri-Alexandre Danlos, who expanded on the findings in 1908. Their combined work led to the naming of the syndrome and laid the foundation for modern understanding.

1901 discovery: Edvard Lauritz Ehlers published a detailed case study of patients with fragile skin and joint hypermobility in a Danish medical journal.
1908 contribution: Henri-Alexandre Danlos independently described similar symptoms, leading to the eventual eponymous naming of the disorder.
Early misdiagnosis: Prior to 1901, EDS symptoms were often mistaken for other rheumatological or dermatological conditions due to overlapping features.
Genetic basis: It wasn’t until the 1990s that researchers identified specific gene mutations responsible for several EDS subtypes.
Global prevalence: Current estimates suggest EDS affects about 1 in 5,000 individuals, though underdiagnosis remains common.

How It Works

Ehlers-Danlos syndrome disrupts the body’s production of collagen, a critical protein for skin, joints, and connective tissues. This malfunction leads to a wide range of systemic symptoms depending on the subtype.

Collagen defect: Mutations in COL5A1, COL5A2, or COL3A1 genes impair collagen synthesis, weakening structural integrity in tissues.
Joint hypermobility: Affected individuals can often extend joints beyond normal range, increasing risk of dislocations and chronic pain.
Skin elasticity: Skin can be stretched 1.5 to 2 times beyond normal limits and snaps back, a hallmark sign of classical EDS.
Vascular complications: The vascular subtype carries a risk of arterial or organ rupture, with a life expectancy of 48 years without careful management.
Diagnostic criteria: The 2017 International Classification requires major and minor clinical signs plus genetic testing for most subtypes.
Inheritance pattern: Most forms follow an autosomal dominant pattern, meaning a 50% chance of passing the mutation to offspring.

Comparison at a Glance

The following table compares major subtypes of Ehlers-Danlos syndrome by key clinical features and prevalence.

Subtype	Prevalence	Key Features	Genetic Cause	Lifespan Impact
Hypermobile (hEDS)	1 in 10,000–15,000	Joint instability, chronic pain	Unknown gene(s)	Minimal if managed
Classical	1 in 20,000–40,000	Skin hyperextensibility, atrophic scars	COL5A1, COL5A2	Normal with care
Vascular	1 in 250,000	Thin skin, visible veins, rupture risk	COL3A1	Reduced (~48 years)
kyphoscoliotic	Rare	Severe scoliosis, eye fragility	PLOD1	Moderate reduction
Arthrochalasia	Extremely rare	Hip dislocation, short stature	COL1A1, COL1A2	Variable

Understanding these differences is critical for diagnosis and management. While hypermobile EDS is most common, vascular EDS poses the greatest health risk due to potential life-threatening complications.

Why It Matters

Recognizing Ehlers-Danlos syndrome early improves outcomes through targeted care and preventive strategies. Despite its rarity, EDS has significant implications for quality of life and long-term health.

Diagnostic delays: Many patients wait 10–15 years for a correct diagnosis, leading to worsening symptoms and complications.
Physical therapy: Custom regimens help stabilize joints and reduce pain in over 70% of hEDS patients.
Cardiovascular monitoring: Regular echocardiograms are recommended for vascular EDS to detect aneurysms early.
Psychosocial impact: Chronic pain and mobility issues contribute to high rates of anxiety and depression in EDS patients.
Research advancements: The 2017 reclassification improved diagnostic accuracy and spurred new gene-targeted therapies.
Public awareness: Advocacy groups have increased visibility, leading to better physician education and earlier interventions.

As genetic testing becomes more accessible, early detection and personalized treatment plans are becoming more feasible, offering hope for improved prognosis across all EDS subtypes.